However, we initially reported that a vaccinia virus-based therapeutic vaccine indiscriminately expanded both CD4+ effector T cells and Tregs in tumor-bearing hosts, resulting compromised antitumor immune responses [81, 82]. The gene discussed is CD4; the disease is neoplasm.